Gilead Sciences (GILD) Net Income towards Common Stockholders (QoQ) (2009 - 2026)

Gilead Sciences (GILD) Net Income towards Common Stockholders (QoQ) (2009 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -20.06%
Dec 31, 2025 -17.17%
Sep 30, 2025 55.63%
Jun 30, 2025 49.13%
Mar 31, 2025 -26.21%
Dec 31, 2024 42.22%
Sep 30, 2024 -22.41%
Jun 30, 2024 138.72%
Mar 31, 2024 -394.56%
Dec 31, 2023 -34.81%
Sep 30, 2023 109.05%
Jun 30, 2023 5.59%
Mar 31, 2023 -39.74%
Dec 31, 2022 -8.57%
Sep 30, 2022 57.36%
Jun 30, 2022 9,358.33%
Mar 31, 2022 -96.81%
Dec 31, 2021 -85.46%
Sep 30, 2021 71.26%
Jun 30, 2021 -11.70%